P Tobase1, H Lane2, A-E-A Siddiqi3, J M Soucie3, R Ingram-Rich4, S Ward5, J C Gill6. 1. Hemophilia Treatment Center, University of California, San Francisco, CA, USA. 2. Intermountain Hemophilia and Thrombosis Center Primary Children's Medical Center, Salt Lake City, UT, USA. 3. Division of Blood Disorders, Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA. 4. LEND@OHSU, Portland, OR, USA. 5. Department of Physical Therapy, University of Utah College of Health, Salt Lake City, UT, USA. 6. Medical College of Wisconsin and Comprehensive Center for Bleeding Disorders, Blood Center of Wisconsin, Milwaukee, WI, USA.
Abstract
BACKGROUND: Invasive orthopaedic interventions (IOI) are often used to control recurrent haemarthrosis, pain and loss of joint function, in males with haemophilia (Factor VIII and Factor IX deficiency). AIM: Identify risk factors associated with IOIs in males with haemophilia enrolled in the Universal Data Collection (UDC) surveillance program from 2000 until 2010. METHODS: Data were collected on IOIs performed on patients receiving care in 130 haemophilia treatment centers in the United States annually by health care providers using standardized forms. IOIs included in this study are as follows: 1) synovectomy and 2) arthrodesis or arthroplasty (A/A). Information about potential risk factors was obtained from the preceding UDC visit if available, or from the same visit if not. Patients with no reported IOI at any of their UDC visits were the reference group for the analysis. Multivariate analyses were conducted to identify independent risk factors for synovectomies and arthrodesis/arthroplasty. RESULTS: Risk factors significantly associated with the two IOI categories were age, student status, haemophilia severity, number of joint bleeds within the last 6 months, HIV or hepatitis C (HCV) status. Multivariate analyses showed patients on continuous prophylaxis were 50% less likely to have had a synovectomy and were 40% less likely to have an A/A. CONCLUSIONS: This study shows modifiable risk factors, including management of bleeding episodes with a continuous prophylactic treatment schedule are associated with a decreased likelihood of IOIs in males with haemophilia.
BACKGROUND: Invasive orthopaedic interventions (IOI) are often used to control recurrent haemarthrosis, pain and loss of joint function, in males with haemophilia (Factor VIII and Factor IX deficiency). AIM: Identify risk factors associated with IOIs in males with haemophilia enrolled in the Universal Data Collection (UDC) surveillance program from 2000 until 2010. METHODS: Data were collected on IOIs performed on patients receiving care in 130 haemophilia treatment centers in the United States annually by health care providers using standardized forms. IOIs included in this study are as follows: 1) synovectomy and 2) arthrodesis or arthroplasty (A/A). Information about potential risk factors was obtained from the preceding UDC visit if available, or from the same visit if not. Patients with no reported IOI at any of their UDC visits were the reference group for the analysis. Multivariate analyses were conducted to identify independent risk factors for synovectomies and arthrodesis/arthroplasty. RESULTS: Risk factors significantly associated with the two IOI categories were age, student status, haemophilia severity, number of joint bleeds within the last 6 months, HIV or hepatitis C (HCV) status. Multivariate analyses showed patients on continuous prophylaxis were 50% less likely to have had a synovectomy and were 40% less likely to have an A/A. CONCLUSIONS: This study shows modifiable risk factors, including management of bleeding episodes with a continuous prophylactic treatment schedule are associated with a decreased likelihood of IOIs in males with haemophilia.
Authors: Luigi P Solimeno; Maria E Mancuso; Gianluigi Pasta; Elena Santagostino; Samantha Perfetto; Pier Mannuccio Mannucci Journal: Br J Haematol Date: 2009-02-22 Impact factor: 6.998
Authors: Janna M Journeycake; Kim L Miller; Alice M Anderson; George R Buchanan; Maureen Finnegan Journal: J Pediatr Hematol Oncol Date: 2003-09 Impact factor: 1.289
Authors: Laura A Schieve; Vanessa R Byams; Brandi Dupervil; Meredith A Oakley; Connie H Miller; J Michael Soucie; Karon Abe; Christopher J Bean; W Craig Hooper Journal: MMWR Surveill Summ Date: 2020-09-04